» Articles » PMID: 12349849

Differential Mechanisms of Action of Interferon-beta and Glatiramer Aetate in MS

Overview
Journal Neurology
Specialty Neurology
Date 2002 Sep 28
PMID 12349849
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Interferon-beta and glatiramer acetate (GA) are the two main groups of drugs used in the treatment of MS. Notably, while both ultimately decrease CNS inflammation, they do so by very different mechanisms. Interferon-beta has potent activity at the blood-brain barrier and impairs the trafficking of inflammatory cells into the CNS. In contrast, GA has negligible effect at the blood-brain barrier, allowing GA-specific T helper 2 lymphocytes to enter the CNS to decrease inflammation through bystander suppression. Other differences are also emphasized. The presence of GA-reactive lymphocytes within the CNS parenchyma may have the additional benefit of conferring neuroprotection through protective autoimmunity.

Citing Articles

The role of CD56 NK cells in neurodegenerative disorders.

Rodriguez-Mogeda C, van Ansenwoude C, van der Molen L, Strijbis E, Mebius R, de Vries H J Neuroinflammation. 2024; 21(1):48.

PMID: 38350967 PMC: 10865604. DOI: 10.1186/s12974-024-03040-8.


Type I/type III IFN and related factors regulate JEV infection and BBB endothelial integrity.

Zhang Y, Zhang H, Chen H, Lv P, Su J, Chen Y J Neuroinflammation. 2023; 20(1):216.

PMID: 37752509 PMC: 10523659. DOI: 10.1186/s12974-023-02891-x.


The Translatability of Multiple Sclerosis Animal Models for Biomarkers Discovery and Their Clinical Use.

Birmpili D, Charmarke Askar I, Bigaut K, Bagnard D Int J Mol Sci. 2022; 23(19).

PMID: 36232832 PMC: 9570245. DOI: 10.3390/ijms231911532.


Recent Advances in Age-Related Macular Degeneration Therapies.

Fabre M, Mateo L, Lamaa D, Baillif S, Pages G, Demange L Molecules. 2022; 27(16).

PMID: 36014339 PMC: 9414333. DOI: 10.3390/molecules27165089.


Innate Lymphoid Cells - Neglected Players in Multiple Sclerosis.

Sadeghi Hassanabadi N, Broux B, Marinovic S, Gotthardt D Front Immunol. 2022; 13:909275.

PMID: 35784374 PMC: 9247827. DOI: 10.3389/fimmu.2022.909275.